Here are the DEF 14A proxy statements from VivoSim Labs, Inc. (VIVS) in our archive over the last 12 months, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A DEF 14A covers the proxy statement, with executive pay and the shareholder votes, so if you follow VIVS and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full VIVS filings page.
VivoSim Labs, Inc. (VIVS) is asking stockholders to vote at a fully virtual annual meeting on September 30, 2026. As of August 13, 2026, the company had 16,586,495 common shares outstanding, its only voting class. Six proposals are up for vote, including electing two Class III directors, ratifying the auditor, an advisory Say‑on‑Pay vote, authorizing a reverse stock split within a 1‑for‑5 to 1‑for‑20 range without reducing authorized shares, a major expansion of the 2022 Equity Incentive Plan, and approval of warrant share issuance and repricing tied to a July 2026 private placement. The equity plan amendment would add 3,165,000 shares for awards, and Proposal 6 would permit issuance of 4,705,883 common shares on warrant exercise and cut the exercise price of May 13, 2024 Investor Warrants from $9.60 to $0.85 per share. The board unanimously recommends voting FOR all proposals and highlights a five‑member board with four independent directors and various governance and compensation "best practice" policies.